Repurposing with a Difference

被引：156

作者：

Boguski, Mark S. ^{[1
,2
]}

Mandl, Kenneth D. ^{[2
,3
]}

Sukhatme, Vikas P. ^{[4
]}

机构：

[1] Harvard Univ, Sch Med, Dept Pathobiol, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA

[2] Harvard Univ, Sch Med, Ctr Biomed Informat, Boston, MA 02115 USA

[3] Harvard Univ, Sch Med, Childrens Hosp Informat Program Harvard MIT, Div Hlth Sci & Technol, Boston, MA 02115 USA

[4] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA

来源：

SCIENCE | 2009年 / 324卷 / 5933期

关键词：

JANUARY-1; FEBRUARY; 2005; DRUG DEVELOPMENT; ABANDONED DRUGS; PHARMACOVIGILANCE; COMMERCIALIZE; PHILADELPHIA; IDENTIFY; DEVELOP; USA; PA;

D O I：

10.1126/science.1169920

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

引用

页码：1394 / 1395

页数：2

共 28 条

[1] Estimating the cost of new drug development: Is it really $802 million? [J].

Adams, CP ;

Brantner, VV .

HEALTH AFFAIRS, 2006, 25 (02) :420-428

[2] Drug repositioning: Identifying and developing new uses for existing drugs [J].

Ashburn, TT ;

Thor, KB .

NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (08) :673-683

[3]

Boguski MS, 2009, GENOMIC AND PERSONALIZED MEDICINE, VOL 1, P252

[4] The Medical Dictionary for Regulatory Activities (MedDRA) [J].

Brown, EG ;

Wood, L ;

Wood, S .

DRUG SAFETY, 1999, 20 (02) :109-117

[5] The Tell-Tale Heart: Population-Based Surveillance Reveals an Association of Rofecoxib and Celecoxib with Myocardial Infarction [J].

Brownstein, John S. ;

Sordo, Margarita ;

Kohane, Isaac S. ;

Mandl, Kenneth D. .

PLOS ONE, 2007, 2 (09)

[6]

Carley DW, 2005, IDRUGS, V8, P310

[7]

Carley DW, 2005, IDRUGS, V8, P306

[8]

Christensen C.M., 2009, INNOVATORS PRESCRIPT

[9] The price of innovation: new estimates of drug development costs [J].

DiMasi, JA ;

Hansen, RW ;

Grabowski, HG .

JOURNAL OF HEALTH ECONOMICS, 2003, 22 (02) :151-185

[10]

Eisenberg Rebecca S, 2005, Yale J Health Policy Law Ethics, V5, P717

← 1 2 3 →